A Study shows mutation-resistant antibodies with 269×affinity, a proof point for CEPI’s 100 Days Mission and closing ...

The Phase 1 study is a randomized, double-blind, placebo-controlled, dose-escalation trial carried out in China, designed to evaluate the safety, tolerability, pharmacokinetics (PK), and ...

"Dosing the first patient in Phase III represents a major milestone for MDR-001 and for AI-enabled drug development," said Zhangming Niu, Founder and Chief Executive Officer of MindRank. "We believe ...

Now, with its new AI-generated arsenal of porosome-targeted peptides and small molecules, the company has expanded emphasis on indications like Parkinson’s disease, Huntington’s disease, and others, ...

Multi-year partnership will utilize Iambic’s broad suite of AI drug discovery technologies and wet lab capabilities to advance collaboration programs initially in Takeda’s Oncology and ...

Overview Artificial intelligence seems to be transforming drug discovery in 2026, enabling faster molecule design, smarter ...

Partnership strengthens Bio-Techne's (TECH) leadership in AI-enabled protein innovation NovoBody™ Duo molecules offer multi-specific binding capabilities for advanced research and diagnostics ...

Researchers will screen 700+ wild yeast strains to build a genomics database and identify species that turn waste into valuable industrial products.

Researchers used a machine learning algorithm powered by a massive network of ordinary smartphones to identify and map out potentially cancer-beating molecules in various foods. The project is ...

Cambridge ag-biotech Bindbridge has raised $3.8m to develop AI-designed molecular glues for next-generation herbicides and ...

Iambic, a clinical-stage life science and technology company developing novel medicines using its AI-driven discovery and development platform, today announced a multi-year technology and discovery ...